SEC Form 4 · accession 0001562180-17-002385
Avalo Therapeutics, Inc. · AVTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Isaac Blech
Director
Period of report
Jun 30, 2017
Accepted (ET)
Jul 5, 2017 · 1:39 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001534120
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F1 | $0.57 | Jun 30, 2017 | A | 36,982 | A | Jun 30, 2017 | Jun 29, 2027 | Common Stock | 36,982 | 36,982 | D |
Explanation of responses
- F1The stock options vested immediately and became exercisable in full upon grant on 6/30/2017.